Design, Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives. 2021

Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
School of Chemical Engineering, Zhengzhou University, Zhengzhou 450001, China.

The chalcone and quinoline scaffolds are frequently utilized to design novel anticancer agents. As the continuation of our work on effective anticancer agents, we assumed that linking chalcone fragment to the quinoline scaffold through the principle of molecular hybridization strategy could produce novel compounds with potential anticancer activity. Therefore, quinoline-chalcone derivatives were designed and synthesized, and we explored their antiproliferative activity against MGC-803, HCT-116, and MCF-7 cells. Among these compounds, compound 12e exhibited a most excellent inhibitory potency against MGC-803, HCT-116, and MCF-7 cells with IC50 values of 1.38, 5.34, and 5.21 µM, respectively. The structure-activity relationship of quinoline-chalcone derivatives was preliminarily explored in this report. Further mechanism studies suggested that compound 12e inhibited MGC-803 cells in a dose-dependent manner and the cell colony formation activity of MGC-803 cells, arrested MGC-803 cells at the G2/M phase and significantly upregulated the levels of apoptosis-related proteins (Caspase3/9 and cleaved-PARP) in MGC-803 cells. In addition, compound 12e could significantly induce ROS generation, and was dependent on ROS production to exert inhibitory effects on gastric cancer cells. Taken together, all the results suggested that directly linking chalcone fragment to the quinoline scaffold could produce novel anticancer molecules, and compound 12e might be a valuable lead compound for the development of anticancer agents.

UI MeSH Term Description Entries
D011804 Quinolines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D017382 Reactive Oxygen Species Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS. Active Oxygen Species,Oxygen Radical,Oxygen Radicals,Pro-Oxidant,Reactive Oxygen Intermediates,Active Oxygen,Oxygen Species, Reactive,Pro-Oxidants,Oxygen, Active,Pro Oxidant,Pro Oxidants,Radical, Oxygen
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047188 Chalcones Derivatives of CHALCONE that are important intermediates in the formation of FLAVONOIDS with anti-fungal, anti-bacterial, anti-inflammatory, and anti-tumor properties. 1,3-Diphenyl-propanediones,1,3-Diphenyl-propenones,1,3-Diphenylpropanediones,1,3-Diphenylpropenones,Chalconoids,1,3 Diphenyl propanediones,1,3 Diphenyl propenones,1,3 Diphenylpropanediones,1,3 Diphenylpropenones
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
January 2017, Iranian journal of pharmaceutical research : IJPR,
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
March 2021, Bioorganic & medicinal chemistry letters,
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
September 2017, Bioorganic & medicinal chemistry letters,
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
June 2015, European journal of medicinal chemistry,
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
December 2019, ACS omega,
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
September 2015, European journal of medicinal chemistry,
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
August 2019, Bioorganic chemistry,
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
September 2019, Molecules (Basel, Switzerland),
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
August 2016, Bioorganic & medicinal chemistry letters,
Yong-Feng Guan, and Xiu-Juan Liu, and Xin-Ying Yuan, and Wen-Bo Liu, and Yin-Ru Li, and Guang-Xi Yu, and Xin-Yi Tian, and Yan-Bing Zhang, and Jian Song, and Wen Li, and Sai-Yang Zhang
January 2022, Frontiers in oncology,
Copied contents to your clipboard!